EXTON, Pa., Oct. 26, 2015 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has presented preclinical data showing the immunosuppressive effects of the CA125 tumor antigen on the investigational humanized anti-folate receptor alpha monoclonal antibody, farletuzumab, at the 19th International Meeting of the European Society of Gynaecological Oncology (http://esgo2015.esgo.org) held October 24-27, 2015 in Nice, France. Previously published work by independent laboratories has shown that the human CA125 tumor antigen may potentially suppress immune-mediated killing of NK (natural killer) cell lymphocytes. A mechanism of NK cell immune-mediated...
↧